BioSpace News Archive

Bioasis Technologies Inc. is pleased to announce that Dr. Deborah Rathjen, Executive Chair will be attending the following industry conferences:.

Galapagos NV and Selvita S.A. announced that the strategic transaction in which Selvita has acquired Fidelta from Galapagos has been completed.

Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced a public offering of 1,750,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (“SEC”).

Rite Aid Corporation announced that Heyward Donigan, president and chief executive officer; Jim Peters, chief operating officer and Matt Schroeder, executive vice president and chief financial officer will participate in a fireside chat with investors at the 39th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11th at approximately 11:40 a.m. ET.

In response to a significant winter storm, the governor of Oklahoma has declared a state of emergency for thirty-nine counties in the state. Blue Cross Blue Shield of Massachusetts (Blue Cross), Inc. is expediting access to care for members who may be affected.

ViewRay, Inc., maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, announced that it has commenced an underwritten public offering of shares of its common stock.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that it submitted an Investigational New Drug (IND) application to

Two different mRNA vaccines have now shown remarkable effectiveness of about 95% in preventing COVID-19 infection in adults.

SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology Publication Affirms SanBio’s Approach to Treating Chronic Traumatic Brain Injury Patients

ViewRay, Inc. announced the pricing of an underwritten public offering of 10,310,000 shares of common stock at a price to the public of $4.85 per share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.